Company profile
Arvelle Therapeutics GmbH (aquired by Angelini Pharma)
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle received one of the largest initial financing commitments for a European-focused biopharmaceutical company.
Source: startup.ch
More news about Arvelle Therapeutics GmbH (aquired by Angelini Pharma)
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
